Even Lower Doses Of SGLT2 Inhibitors Effective For Renoprotection In Type 2 Diabetes

● The findings revealed that Canagliflozin 100 mg demonstrated a distinct eGFR benefit, with an odds ratio of 2.3 (95% confidence interval 0.72–3.9), compared to placebo.

● ‘However, statistically non-significant eGFR benefits were observed with other "-flozins."

● Interestingly, the study indicated that renoprotective efficacy was not dose-dependent, suggesting that lower doses of SGLT2i may be sufficient to achieve favourable renal outcomes.

● In terms of the SUCRA ranking, Canagliflozin 100 mg exhibited the highest probability score of 93%, followed by Canagliflozin 300 mg and Dapagliflozin 5 mg, with sucra rank probability scores of 69% and 65%, respectively.

● These results were consistent when evaluating albumin-creatinine ratios as a secondary endpoint.

Overall, the study highlights the independent renoprotective efficacy of SGLT2i, emphasizing that incremental doses may not be necessary to achieve optimal renal outcomes. This finding could have significant implications for the treatment of individuals with Type 2 diabetes, as lower doses of SGLT2i may not only be effective but also potentially reduce the risk of adverse events associated with higher dosages.

Further research and validation are needed to solidify these findings. However, if confirmed, the use of lower doses of SGLT2 inhibitors for renoprotection could simplify treatment regimens and improve patient compliance. The potential to achieve significant renal benefits with reduced drug dosages represents a step forward in optimizing the management of renal complications in individuals with Type 2 diabetes.

Reference:

Hegde, N. C., Kumar, A., Patil, A. N., Bhattacharjee, S., Gamad, N., Kasudhan, K. S., Kumar, V., & Rastogi, A. (2023). Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis. Acta Diabetologica. https://doi.org/10.1007/s00592-023-02126-8